X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (11) 11
humans (10) 10
index medicus (9) 9
middle aged (9) 9
aged (8) 8
chemotherapy (8) 8
adult (7) 7
cancer (7) 7
female (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
male (6) 6
disease-free survival (5) 5
analysis (4) 4
breast neoplasms - drug therapy (4) 4
indoles - adverse effects (4) 4
pyrroles - adverse effects (4) 4
therapy (4) 4
treatment outcome (4) 4
tyrosine kinase inhibitor (4) 4
adenocarcinoma (3) 3
aged, 80 and over (3) 3
anaplastic lymphoma (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
bevacizumab (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
care and treatment (3) 3
disease progression (3) 3
double-blind (3) 3
drug therapy (3) 3
indoles - administration & dosage (3) 3
kaplan-meier estimate (3) 3
lung cancer (3) 3
metastasis (3) 3
non-small cell lung carcinoma (3) 3
patients (3) 3
pyrroles - administration & dosage (3) 3
young adult (3) 3
1st-line treatment (2) 2
androstadienes - adverse effects (2) 2
aromatase inhibitors - adverse effects (2) 2
bone density - drug effects (2) 2
breast cancer (2) 2
breast neoplasms - pathology (2) 2
carboplatin (2) 2
carboplatin - administration & dosage (2) 2
cisplatin (2) 2
cisplatin - administration & dosage (2) 2
crizotinib (2) 2
diarrhea (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
endothelial growth-factor (2) 2
fatigue - chemically induced (2) 2
indoles - therapeutic use (2) 2
kinase (2) 2
lipids - blood (2) 2
lung neoplasms - drug therapy (2) 2
neoplasm metastasis (2) 2
oncology, experimental (2) 2
paclitaxel (2) 2
pemetrexed (2) 2
placebo (2) 2
postmenopausal women (2) 2
postmenopause (2) 2
prednisone - administration & dosage (2) 2
prednisone - adverse effects (2) 2
prednisone - therapeutic use (2) 2
prostatic neoplasms, castration-resistant - drug therapy (2) 2
pyrroles - therapeutic use (2) 2
rearrangement (2) 2
receptor protein-tyrosine kinases - antagonists & inhibitors (2) 2
research (2) 2
retrospective studies (2) 2
solid tumors (2) 2
su11248 (2) 2
survival (2) 2
taxoids - therapeutic use (2) 2
trial (2) 2
tumors (2) 2
urology & nephrology (2) 2
1st-line therapy (1) 1
2nd-line chemotherapy (1) 1
80 and over (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
abridged index medicus (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma; adult; aged; anaplastic lymphoma kinase; antineoplastic combined chemotherapy protocols; carboplatin; carcinoma, non-small-cell lung; cisplatin; crizotinib; disease-free survival; female; glutamates; guanine; humans; kaplan-meier estimate; lung neoplasms; male; middle aged; pemetrexed; protein kinase inhibitors; pyrazoles; pyridines; receptor protein-tyrosine kinases; medicine (1) 1
adenocarcinoma; adult; aged; antineoplastic combined chemotherapy protocols; carboplatin; carcinoma, non-small-cell lung; cisplatin; disease-free survival; female; glutamates; guanine; humans; kaplan-meier estimate; lung neoplasms; male; middle aged; pemetrexed; protein kinase inhibitors; pyrazoles; pyridines; receptor protein-tyrosine kinases (1) 1
adjuvant tamoxifen (1) 1
adjuvant therapy (1) 1
adolescent (1) 1
advanced breast cancer (1) 1
advanced prostate cancer (1) 1
alectinib (1) 1
aliens (1) 1
alkaline phosphatase - blood (1) 1
anaplastic large-cell lymphoma (1) 1
anaplastic lymphoma kinase - antagonists & inhibitors (1) 1
anaplastic lymphoma kinase - genetics (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 2, pp. 76 - 82
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2870 - 2878
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2251 - 2258
Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK)... 
TRIALS | ONCOLOGY | CERITINIB | ADENOCARCINOMA | ALECTINIB | INHIBITORS | PHASE-3 | RETROSPECTIVE ANALYSIS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 24, pp. 2858 - 2865
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 14, pp. 1405 - 1411
PurposeApproximately 1% to 2% of non-small-cell lung cancers (NSCLCs) harbor a c-ros oncogene 1 (ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic... 
REARRANGEMENT | RET | THERAPY | ONCOLOGY | ADENOCARCINOMA | KINASE | RESISTANCE | MUTATIONS | INHIBITOR | ROS1 FUSION | CHEMOTHERAPY
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Journal Article
BJU International, ISSN 1464-4096, 12/2014, Volume 114, Issue 6b, pp. E25 - E31
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 4342 - 4342
Abstract Introduction Crizotinib (Xalkori®) is an ALK inhibitor with proven efficacy in patients with ALK-rearranged advanced non-small cell lung cancer... 
Journal Article
Clinical Genitourinary Cancer, ISSN 1558-7673, 2014, Volume 12, Issue 5, pp. 317 - 324
Journal Article